The DOI matches its Crossref record; 177 of the 181 references it cites were found in a registry or an index.
American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm—2023 update
Abstract
OBJECTIVE This consensus statement provides (1) visual guidance in concise graphic algorithms to assist with clinical decision-making of health care professionals in the management of persons with type 2 diabetes mellitus to improve patient care and (2) a summary of details to support the visual guidance found in each algorithm. METHODS The American Association of Clinical Endocrinology (AACE) selected a task force of medical experts who updated the 2020 AACE Comprehensive Type 2 Diabetes Management Algorithm based on the 2022 AACE Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan and consensus of task force authors. RESULTS This algorithm for management of persons with type 2 diabetes includes 11 distinct sections: (1) Principles for the Management of Type 2 Diabetes; (2) Complications-Centric Model for the Care of Persons with Overweight/Obesity; (3) Prediabetes Algorithm; (4) Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Dyslipidemia; (5) Atherosclerotic Cardiovascular Disease Risk Reduction Algorithm: Hypertension; (6) Complications-Centric Algorithm for Glycemic Control; (7) Glucose-Centric Algorithm for Glycemic Control; (8) Algorithm for Adding/Intensifying Insulin; (9) Profiles of Antihyperglycemic Medications; (10) Profiles of Weight-Loss Medications (new); and (11) Vaccine Recommendations for Persons with Diabetes Mellitus (new), which summarizes recommendations from the Advisory Committee on Immunization Practices of the U.S. Centers for Disease Control and Prevention. CONCLUSIONS Aligning with the 2022 AACE diabetes guideline update, this 2023 diabetes algorithm update emphasizes lifestyle modification and treatment of overweight/obesity as key pillars in the management of prediabetes and diabetes mellitus and highlights the importance of appropriate management of atherosclerotic risk factors of dyslipidemia and hypertension. One notable new theme is an emphasis on a complication-centric approach, beyond glucose levels, to frame decisions regarding first-line pharmacologic choices for the treatment of persons with diabetes. The algorithm also includes access/cost of medications as factors related to health equity to consider in clinical decision-making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While recent guidelines call for continuous glucose monitoring (CGM) use for all who require insulin, regardless of diabetes type (7), there is also evidence that patients may not know how to interpret what to do with the CGM data (6, 8, 9).”
From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [7]
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., Simons-Morton, D. G., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440101 · Cited by 5,638
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Research works printed but not linked: 2
- 2008, Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545
- Mechanick, 2019, Endocr Pract, 25, 1346
Cited by
Sorted by citations
Items 301–373 of 373
Millhuff, A., & Blankenship, J. C. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07727-9
“SGLT2 inhibitors are also indicated for patients with type 2 diabetes mellitus for glycemic control [2].”
Cokro, F., Sauriasari, R., Tahapary, D. L., Setiawan, H., Tricaesario, C., Hidayati, N., & Soegondo, S. (2025) · F1000Research · doi:10.12688/f1000research.163923.1
Non-pharmacologic Interventions for Type 2 Diabetes
Dyke, A. V., & Lacey, C. (2025) · Springer eBooks · doi:10.1007/978-3-031-88835-9_3
Hsieh, J.-C. J., Bagha, Z. M., Weintraub, S. F., Jnani, J., & Block, L. (2025) · Cureus · doi:10.7759/cureus.87718
“…ratings of knowledge of the 2023 American Diabetes Association (ADA) Guidelines (pre 1 (1-2) vs. post 4 (3-4), W = 78, p 0.01) and ratings of knowledge of the 2023 American Association of Clinical Endocrinology (AACE) Consensus Statement (pre 1 (1-2) vs. post 4 (3-4), W = 91, p < 0.01) [13,14].”
InfluentialГеннадьевна, Н. А., & Каретникова, В. Н. (2025) · Cardiosomatics · doi:10.17816/cs676532
Unnikrishnan, A. G., Bhake, R. C., Sahay, R. K., Chandra, S., Abdullakutty, J., Rastogi, A., Behl, A., Sharma, K. H., Lakhani, O., Sarkar, P., et al. (2025) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_11_25
Cokro, F., Sauriasari, R., Tahapary, D. L., Setiawan, H., Tricaesario, C., Hidayati, N., & Soegondo, S. (2025) · F1000Research · doi:10.12688/f1000research.163923.2
Kumar, K. P. N. S., Variam, M. T., Bala Vignesh, S., Nath, K., Goyal, K. K., Beswal, G., Arun, P., Narayan, K., Kumar, S. P. S., Ravindranath, V., et al. (2025) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000334
“…Clinical Practice Guideline update on a comprehensive T2DM care plan recommends that if there is an established or high risk of HF, clinicians should prescribe an SGLT2 inhibitor or a glucagon-like peptide-1 (GLP-1) receptor agonist with proven efficacy, independent of glycemic control [12].”
El‐Sheikh, M., Sillassen, C. D. B., Wisborg, F. D., Hove, J. D., Dirksen, C., Lee, M. M. Y., Jakobsen, J. C., & Grand, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-103668 · Cited by 1
“43 However, GLP-1 RAs significantly decreased HF hospitalisations and cardiovascular death in patients without a history of HF but did not provide these benefits in those with a history of HF.”
InfluentialCase reports from individual consultations provided to patients in the pharmacy
Kolmanová, E., & Malý, J. (2025) · Česká a slovenská farmacie · doi:10.36290/csf.2025.031
Zinych, О. В., Stepanov, Y. M., Shyshkan-Shyshova, К. О., Кленіна, І. А., Кушнарьова, Н. М., Ковальчук, А., & Prybyla, О. В. (2025) · Endokrynologia · doi:10.31793/1680-1466.2025.30-2.142
Caring Under Constraints: A Qualitative Study of Parental Needs in Pediatric Diabetes in Zabol
Hedayati, S. P., Sotoudeh, A., & Mohabati, F. (2025) · Pediatric Diabetes · doi:10.1155/pedi/4306754
“…the International Society for Pediatric and Adolescent Diabetes (ISPAD) and the American Diabetes Association (ADA), emphasize the importance of individualized insulin therapy, structured diabetes education, and careful monitoring to support both medical outcomes and psychosocial adjustment [5, 6].”
Porterfield, L. R., Yu, X., Amspoker, A. B., Johnston, C. A., Naik, A. D., Virani, S. S., Ballantyne, C. M., Balasubramanyam, A., & Vaughan, E. M. (2025) · Innovation in Aging · doi:10.1093/geroni/igaf121
Malloy, J., & Bird, S. (2025) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.09.003
Early glycemic control and subsequent risk of incident dementia among new metformin users
Power, M. C., Madsen, M., Bødkergaard, K., Zimmerman, S. C., Ackley, S. F., Gilsanz, P., Glymour, M. M., Henderson, V. W., Sørensen, H. T., & Thomsen, R. W. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.10.017 · Cited by 4
Glucagon-Like Peptide-1 Receptor Agonists
Whitley, H. P. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch13
Schmiedel, O., Ivey, M. K., Karunasinghe, N., & Murphy, R. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100240
“Such a phenotype targeted approach would be used in addition to selecting medications based on potential medication interactions, comorbidities, affordability or risk of adverse events in the process of personalizing care [8,9].”
Hassanein, M. M., Alessa, T., Hafidh, K., Alzubaidi, L. M. Y., Jallo, M. K. I., Slail, F. Y. A., Elbadawi, H., & Malik, R. A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01824-6
“Most guidelines recommend tailoring treat-ment regimens and targets/goals based on cardiovascular (CV) risk, comorbidities, psychosocial factors, and individual preferences [9–11].”
InfluentialAdditional file 2 of Oral-gut microbial transmission promotes diabetic coronary heart disease
Li, Y., Liu, Y., Cui, J., Zhu, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26702902
Csatordai, M., Benkő, R., Matúz, M., Engi, Z., Csupor, D., Lengyel, C., & Doró, P. (2024) · Figshare · doi:10.6084/m9.figshare.26711594
Additional file 1 of Oral-gut microbial transmission promotes diabetic coronary heart disease
Li, Y., Liu, Y., Cui, J., Zhu, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26702899
Csatordai, M., Benkő, R., Matúz, M., Engi, Z., Csupor, D., Lengyel, C., & Doró, P. (2024) · Figshare · doi:10.6084/m9.figshare.26711591
Csatordai, M., Benkő, R., Matúz, M., Engi, Z., Csupor, D., Lengyel, C., & Doró, P. (2024) · Figshare · doi:10.6084/m9.figshare.26711588
Keister, D., Lorenzen, S., Clemons, M., Renner, S. A., & Tasma, B. (2025) · JAPhA Practice Innovations · doi:10.1016/j.japhpi.2025.100086
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408479-references
Nuevo algoritmo de redGDPS 2026: de la glucemia al paciente
Soidán, F. J. G., Menéndez, S. A., Lachica, L. Á., Pato, Ó. B., Pradas, N. C., Teixidó, C. H., Vela, N. S., Mera-Gallego, I., & Carretero-Anibarro, E. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.4.art2
Karimi, N., CHOI, S. E., Song, Y., & Tolentino, D. A. (2026) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000001237
Diagnosis and risk factors in pancreatogenic diabetes
Sharma, R. K., Singh, A., & Dawra, S. (2026) · Advances in clinical chemistry · doi:10.1016/bs.acc.2025.10.003 · Cited by 1
Si, S., Wang, R., Li, J., Ding, Y., Liu, Y., & Osumili, B. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2025.2604454
Sharba, I. R., ABDULRAHMAN, B. A., Sarhan, D. K., & Kazim, F. K. (2025) · Al-Kufa University Journal for Biology · doi:10.36320/ajb/v17.i3.21730
Bhattacharya, S., van Helvoort, A., Schols, A. M. W. J., & Sambashivaiah, S. (2026) · Contemporary Clinical Trials · doi:10.1016/j.cct.2026.108228
Wei, B., Gao, T., & Liu, Q. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1721267
Teküstün, G. N., Gurel, B. H. Y., Kitaplı, S., Alkan, A., & Tanrıverdi, Ö. (2026) · Endocrine · doi:10.1007/s12020-026-04553-3
Erande, S. G., Raykantiwar, A., Samadhan, S. V., Rashmi, G. R., Maiti, A., Kartheek, A. S. V., Hanifah, M., Giri, R., GADVE, S. S., Ray, A., et al. (2026) · Cureus · doi:10.7759/cureus.103676
“Particularly, for long-term durable glycemic control, early combination therapy should be considered for all patients with HbA1c levels of 7.5% or higher [6].”
InfluentialHsu, H.-Y., & Shi, H.-Y. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113186
Kanumilli, N., Osumili, B., Evans, J., Webb, J., Buckingham, M., Debackere, N., Nowakowski, P., Cattin, J., & Hunt, B. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2631920
Xu, X., Wang, X., Ouyang, L., Xu, F., Xu, W., Wen, X., & Yam, M. F. (2026) · Research Square · doi:10.21203/rs.3.rs-8894614/v1
Nutritional considerations for athletes with diabetes: optimizing performance and glycemic control
Xu, L., & Zhang, W. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1737219
“However, as the AID might offer more insulin when blood glucose starts to rise after consuming carbs without bolus coverage, it is recommended to avoid eating more than half an hour before exercise (61).”
Medication Deprescribing Practices Among Lifestyle Medicine Providers: A Cross-Sectional Survey
MacField, J. F., Staffier, K. L., Kelly, J. H., Moghe, R. A., & Karlsen, M. C. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261430281
Linagliptin in type 2 diabetes mellitus: glycemic control and beyond
Agrawala, R. K., Patra, J., Sowmiya, M., & Revankar, S. Y. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20260995
Ding, X., Vadini, V., Kim, C., Bu, F., Chen, H. Y., Chai, Y., Duarte‐Salles, T., Hsu, J. C., Khera, R., Lau, W. C. Y., et al. (2026) · medRxiv · doi:10.64898/2026.04.10.26350252
Saab, C., Mansour, A. A., Rahmah, A. M., Al-Attar, D. M. R. A., Alrubaye, H. F., Alidrisi, H. A., Nwayyir, H. A., Khudhair, M. S., Ahmed, M. J., AL-Ibrahimi, S. M., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01861-9
“Latest insulin thera‑ pies of BI with GLP‑1 RAs FRC such as iGlar‑ Lixi (currently the only available FRC in Iraq), address these challenges by reducing hypogly‑ cemia risk and maintaining weight neutrality compared to intensive insulin regimens [30, 41, 42].”
Jodłowska-Siewert, E., Chen, Y., Zhang, S., Li, J., Dellavalle, R. P., Zhang, R., & Hou, J. (2026) · JMIR Diabetes · doi:10.2196/85083
“There is no single straightforward T2D treatment regime sequence [18], and in some patients, clinical practitioners choose between insulin and sulfonylureas.”
Alawadi, F., Abdelgadir, E., Hassoun, A. A. K., Abusnana, S., Afandi, B. O., Aldahmani, K. M., Alkaabi, J., Bashier, A. M., Bayado, F., Belaila, B. A. B., et al. (2026) · Dubai Diabetes and Endocrinology Journal · doi:10.18502/ddej.v32i1.21067
Garcia, S., O'Donnell, R. M., Schlichte, A., & Zagel, A. L. (2026) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2026.103110
Mihich, A., Caranti, S., & Verna, R. (2026) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-026-01421-9
Lee, E. J., Lee, G. B., Her, Y. S., Shin, K. E., Cho, K.-H., Han, K., Chang, N.-W., Lee, Y., Han, B., & Kim, Y. (2026) · Clinical and Experimental Dental Research · doi:10.1002/cre2.70371
Kong, C. Y. A., Amaravadi, S. K., Costa, J., Ferreira, A. D. S., Vigário, P. D. S., & Alaparthi, G. K. (2026) · F1000Research · doi:10.12688/f1000research.180073.1
Chomko, M. (2026) · American Diabetes Association eBooks · doi:10.2337/9781580408493-ch05
Dapagliflozin in acute myocardial infarction with type 2 diabetes: a randomized clinical trial
Macías-Cervantes, H. E., Guardado‐Mendoza, R., González, L. J., Bautista-López, G. R., Hernández-Tizapa, K., Carrillo-Torres, M. Á., Fernández-Yáñez, G., Hinojosa-Gutiérrez, L. R., Ruiz, E. A. B., Cárdenas-Muñoz, M. E., et al. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103401
Kotlyarov, S. N., & Котлярова, А. А. (2026) · Pharmacoepidemiology · doi:10.3390/pharma5030025
“…obesity and high cardiovascular risk, as well as in cases of inadequate response to metformin, current guidelines prioritize these classes of drugs based on their proven ability to achieve significant weight loss, improve glycemic control, and reduce the risk of cardiovascular events [13,15–17].”
Deka, N., Das, S., Modi, K. D., Gupta, A. D., Gupta, M., Chhabra, A., Mishra, N. K., Goroshi, M., Soneja, H., Agarwal, S., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_10_26
Oser, S. M., Crystal, C., Hames, K. C., Li, X., Gao, P., Crawford, M. A., Hicks, C., Gerber, M., Gautier, T., Colmegna, P. H., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01901-4
“Titration algorithms typically recommend dose changes based on FBG values [20–22], but with one of the most common reasons for clinical inertia and not intensifying basal insulin therapy being fear of hypoglycemia [4, 6], a CGM-inte-grated basal insulin optimizer that incorporates CGM data from the…”
Ma, J., & Zhen, L. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1889568
Liu, Y., Zheng, S., Yu, Z., Zhao, R., Li, Q., li, S., & Chen, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71221
Wu, B., Huang, Y., Yang, D., Li, Z., Wang, L., & Fu, C. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-124032
Selvaganesan, P., Karnib, M., Helmy, I., Reddy, Y. N. V., Osman, M., Sahadevan, J., Zakeri, R., & Sundaram, V. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002380
“14 Comparing drugs used at a similar stage of treatment helps minimise confounding by indication.”
Perioperative Management of Patients Taking GLP-1 Receptor Agonists. A Mini-Review
Smilková, L. H., & Záhorec, R. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00825-6
“In diabetic patients at high risk for atherosclerotic cardiovascular disease, GLP-1RAs are recommended as first-line therapy by both endocrinology and cardiology societies [ 3, 4, 5].”
Wang, X., Huang, J., Xu, T., Zhang, Z., Luo, C., Tan, Y., Wang, H., & Xu, R. (2026) · Journal of Medical Internet Research · doi:10.2196/90796
“From a management perspective, endocrinology wards adopt guideline-driven approaches supported by multidisciplinary teams, enabling precision glycemic management strategies consistent with the model proposed by Samson and colleagues [29].”
Smith, C. R. (2026) · Considerations in Medicine · doi:10.1136/conmed-2026-000055
Leite, A. R., Ramalho, C., Ramos, D., Marcelino, M., Melo, M., Freitas, P., Maricoto, T., Pinto, F., do Vale, S., Calçada, E., et al. (2026) · Acta Médica Portuguesa · doi:10.20344/amp.24706
Hageen, A. W., Gadelmawla, A. F., Saleh, A. O., Bahnasy, S., Eladawi, S., Abdelaziz, M., Iyad, K., Kandil, A. H., Zinhom, K., Reyad, M., et al. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70313
Glycemic control and long-term macrovascular outcomes in people with type 2 diabetes in China
Sun, F., Pan, Q., Zhang, M., Shen, P., Sun, Y., Lin, H., Zhan, S., & Guo, L. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004266
“[2] Some guidelines, such as the American Association of Clinical Endocrinology, [3] suggest a more stringent target (HbA1c ≤ 6.5%).”
InfluentialBech, J. N., McCormack, T., Bhalla, V., Ben-Dor, N., Segura, J., Christiansen, S. H., Andersen, I. T., Erhard, C., Rhodes, K. M., Norris, T., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03771-5
Wang, D., Nida, G., Hardesty, V., & Livingston, K. A. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261488712
GLP-1 receptor agonists in obesity treatment: where we are today and what can we expect?
Pichlerová, D. (2026) · Vnitřní lékařství · doi:10.36290/vnl.2026.070
Eliseeva, E. M., Druzhinina, A. A., & Chistokhina, A. A. (2026) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2026-14-3-249-262
Diretriz Brasileira de Cardiogeriatria – 2026
Helber, I., Zanon, J. C. D. C., Peixoto, J. M., Caixeta, A. M., Nussbacher, A., de Oliveira, D. C., de Freitas, E. V., Cintra, F. D., Garcia, J. S., Miranda, R. D., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260795
Qadeer, A., Khalid, M. B., LeBlanc, D. P., Graves, T. D., Malik, M. A., Forrester, A., Juarez, L. M., Albayyaa, M., Allencherril, J., Blackwell, T. A., et al. (2026) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468261496357
Zhou, Y., Li, J., Wu, Y., 邱琳, Chen, X., Wang, M., Li, L., Wang, Y., & Xu, M. (2026) · Sleep Medicine · doi:10.1016/j.sleep.2026.109317
The Impact of Complementary Therapy on Diabetes Mellitus Patients: A Review
., S., Andika, I. P. J., Christina, T. Y., Yulianti, T. S., Rizki Aqsyari., D., Sakinah, S., Handayani, W., & Baso, Y. S. (2026) · Malaysian Journal of Medicine and Health Sciences · doi:10.47836/mjmhs.22.s9.48
Giorgino, F., Haluzı́k, M., Alvarez, A., Lauand, F., Assaad-Khalil, S. H., Thacker, H. P., Klupa, T., Deyneli, O., & Rosenstock, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71436
Metadata
- Authors
- Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., Umpierrez, G. E., & Valencia, W. M.
- Affiliations
- Mayo Clinic (US)
- Grady Memorial Hospital (US)
- Ochsner Health System (US)
- Indiana University Columbus (US)
- University of Miami (US)
- University of Washington (US)
- Emory University (US)
- University of Nevada, Las Vegas (US)
- Maine Medical Center (US)
- Cleveland Clinic (US)
- ORCID
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2023-05
- Volume
- 29
- Issue
- 5
- Pages
- 305-340
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W4372214811
- Semantic Scholar
- 066a5bccabf1b093084ed77c43509daa1c94c321
- Cited by
- 375
- References
- 181
- Citations by year
- 2026: 62 · 2025: 150 · 2024: 124 · 2023: 38
- FWCI
- 76.07
- Type
- journal article
- Language
- en
- Update notices
- Open access
- closed
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK123384)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, prediabetes, glycemic control, dyslipidemia, hypertension, insulin intensification, antihyperglycemic medications, anti-obesity drugs, obesity, lifestyle modification, health equity
- MeSH terms
- Endocrinologists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Endocrinology, Glucose, Humans, Hypertension, Obesity, Prediabetic State, United States, Dyslipidemias, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
